ABSTRACT
The annual "Antibody Industrial Symposium", co-organized by LabEx MAbImprove and MabDesign, held its 10th anniversary edition in Montpellier, France, on June 28-29, 2022. The meeting focused on new results and concepts in antibody engineering (naked, mono- or multi-specific, conjugated to drugs or radioelements) and also on new cell-based therapies, such as chimeric antigenic receptor (CAR)-T cells. The symposium, which brought together scientists from academia and industry, also addressed issues concerning the production of these molecules and cells, and the necessary steps to ensure a strong intellectual property protection of these new molecules and approaches. These two days of exchanges allowed a rich discussion among the various actors in the field of therapeutic antibodies.
Subject(s)
Antibodies, Monoclonal , Immunotherapy, Adoptive , Antibodies, Monoclonal/therapeutic use , FranceABSTRACT
Pyrene excimer fluorescence is effectively quenched by non-nucleosidic perylene diimides upon DNA duplex formation.
Subject(s)
DNA/chemistry , Imides/chemistry , Perylene/analogs & derivatives , Circular Dichroism , Fluorescence , Molecular Structure , Perylene/chemistry , Spectrophotometry , TemperatureABSTRACT
There is today a blatant need for new antifungal agents, because of the recent increase in life-threatening infections involving an ever-greater number of fungal strains. Fungi make extensive use of kinases in the regulation of essential processes, in particular the cell cycle. Most fungal kinases, however, are shared with higher eukaryotes. Only the kinases which have no human homologs, such as the histidine kinases, can be used as targets for antifungal drugs design. This review describes efforts directed towards the discovery of drugs active against a novel target, the atypical cell cycle kinase, Civ1.
